Organigram Global has entered into an agreement to acquire Aurora Cannabis in a transaction valuing Aurora at approximately C$561 million on a fully diluted equity basis. The proposed combination will bring together two Canadian cannabis producers with complementary operations across recreational and medical markets in Canada, Europe, Australia, and other international regions.
Under the arrangement agreement, Aurora shareholders will receive consideration valued at C$7.80 per share.
The offer represents a 93% premium to Aurora’s unaffected closing share price on August 10, 2026, before Curaleaf announced its intention to pursue a hostile takeover.
It also represents a 21% premium to the value of Curaleaf’s competing offer, as measured by the companies in their announcement.
The proposed transaction provides Aurora shareholders with several consideration alternatives.
They can elect to receive C$7.80 in cash per share, 5.8626 Organigram shares per Aurora share, or a combination of C$3.75 in cash and 3.0431 Organigram shares.
Cash and share elections will be subject to proration under the transaction agreement.
The aggregate consideration will include no more than approximately 205.8 million Organigram shares and C$253.6 million in cash.
Following completion, Aurora shareholders are expected to hold approximately 35% of the combined company’s economic ownership and 42% of its voting rights.
The acquisition is intended to establish a larger international cannabis business with complementary production and distribution capabilities.
Organigram contributes its Canadian recreational cannabis operations, product development capabilities, and expanding European medical business.
Aurora contributes an established international medical cannabis platform and manufacturing infrastructure certified to European pharmaceutical standards.
The combination is expected to strengthen the company’s position in markets with established national cannabis regulations.
Organigram and Aurora anticipate identifying more than C$50 million in synergies through purchasing efficiencies, shared distribution, administrative savings, and other operational improvements.
The combined organization also expects opportunities to coordinate manufacturing across different locations and expand product distribution.
British American Tobacco, an existing strategic investor in Organigram, is supporting the acquisition.
Its subsidiary, BT DE Investments, has agreed to invest approximately C$187.5 million through a concurrent private placement.
The investment involves the purchase of approximately 141 million Organigram shares at C$1.33 per share.
Preferred shares may be issued in place of common shares where necessary to maintain applicable ownership limits.
Organigram is also arranging additional financing through ATB Financial.
The lender has committed up to C$210 million in senior secured credit facilities, including revolving and term loan arrangements.
These facilities are intended to support the transaction while preserving financing flexibility.
The acquisition follows a strategic review by Aurora’s independent directors.
Aurora’s Board unanimously determined that the Organigram proposal was preferable to Curaleaf’s hostile offer.
The company has recommended that shareholders reject the competing bid and support the Organigram transaction.
Organigram’s Board also approved the transaction, subject to the applicable voting and regulatory requirements.
Shareholder meetings are expected in December 2026.
Completion is anticipated in January 2027, subject to shareholder, court, and regulatory approvals.
The proposed acquisition would establish a larger cannabis company with expanded international distribution, manufacturing capabilities, and financial resources.
KEY QUOTES:
“This Transaction is a defining step in Organigram’s strategy to build a disciplined, global cannabis leader. By bringing together Aurora’s established global medical cannabis platform with our Canadian operations and growing international footprint, we are creating a larger, stronger, and more diversified company. We are excited to build on our complementary operations, expertise, capital resources, and cultures to accelerate growth, meet the growing global demand, and drive long-term profitable growth.”
James Yamanaka, CEO Of Organigram
“Combining with Organigram will accelerate Aurora’s international growth strategy by strengthening commercial execution, expanding our product and R&D capabilities, and extending our global operating network. For Aurora’s shareholders, the Transaction is the result of a robust strategic review process and delivers compelling value today, meaningful choice in how they receive it and the opportunity to participate in the future of a leading cannabis company.”
Miguel Martin, Executive Chairman And CEO Of Aurora

